EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of Human Serum Albumin Nanoparticles for Rapamycin Delivery

Camila Fernanda Rodero iD, Cristina Pangua, Jorge Morales Gracia, Melibea Berzosa Suner, Marcela Tavares Guiguer, Marlus Chorilli iD, Juan M Irache iD

ACS Omega · 18.08.2026 · 11 (32) · 47730-47738

DOI: 10.1021/acsomega.6c02977 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Omega, online erschienen am 04.08.2026. Verfasst von Camila Fernanda Rodero und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University, Araraquara 14800-903, Brazil. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Funda??o de Amparo ? Pesquisa do Estado de S?o Paulo, Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior, Programa de Apoio ao Desenvolvimento Cient?fico-Faculdade de Ci?ncias Farmac?uticas.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rapamycin (RAP) is a macrolide antibiotic with potent immunomodulatory and anticancer properties, but its clinical use is hindered by poor solubility, chemical instability, and limited bioavailability. The aim of this study was the development of PEG-coated albumin nanoparticles for delivering rapamycin and maintaining its biological activity after encapsulation. Rapamycin-loaded albumin nanoparticles were prepared by desolvation of an aqueous solution of the protein with ethanol and subsequent coating with PEG 35,000. The resulting nanoparticles (NPA-RAP) displayed adequate physicochemical properties for intravenous delivery, including sizes within the tumor-targeting range (150–200 nm), low polydispersity (<0.2), and negative zeta potential (∼−30 mV). PEGylation and surface charge ensured short-term stability, while encapsulation efficiency exceeded 70%, with sustained biphasic release (40% over 24 h) well described by the Weibull model. In vitro, NPA-RAP showed cytotoxicity in MCF-7 breast cancer cells comparable to free rapamycin but with lower IC50 values. In Caenorhabditis elegans, NPA-RAP did not affect fat content but extended lifespan by ∼70%, outperforming free rapamycin. These results suggest that these nanoparticles can successfully transport rapamycin without causing detectable carrier-induced toxicity, highlighting its promise for further therapeutic assessment.

Autor:innen und Institutionen

  • Department of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University, Araraquara 14800-903, Brazil.
  • Department of Pharmaceutical Sciences, University of Navarra, Pamplona 31008, Spain.
  • Department of Microbiology and Parasitology, University of Navarra, Pamplona 31008, Spain.

ORCID-Profile: Camila Fernanda Rodero, Marlus Chorilli, Juan M Irache

Förderung

  • Funda??o de Amparo ? Pesquisa do Estado de S?o Paulo
  • Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior
  • Programa de Apoio ao Desenvolvimento Cient?fico-Faculdade de Ci?ncias Farmac?uticas

Zitieren

APA

Rodero, C. F., Pangua, C., Gracia, J. M., Suner, M. B., Guiguer, M. T., Chorilli, M., & Irache, J. M. (2026). Evaluation of Human Serum Albumin Nanoparticles for Rapamycin Delivery. ACS Omega, 11(32), 47730-47738. https://doi.org/10.1021/acsomega.6c02977

Vancouver

Rodero CF, Pangua C, Gracia JM, Suner MB, Guiguer MT, Chorilli M, et al. Evaluation of Human Serum Albumin Nanoparticles for Rapamycin Delivery. ACS Omega. 2026;11(32):47730-47738. doi:10.1021/acsomega.6c02977

BibTeX
@article{Rodero2026,
  author = {Rodero, Camila Fernanda and Pangua, Cristina and Gracia, Jorge Morales and Suner, Melibea Berzosa and Guiguer, Marcela Tavares and Chorilli, Marlus and Irache, Juan M},
  title = {Evaluation of Human Serum Albumin Nanoparticles for Rapamycin Delivery},
  journal = {ACS Omega},
  year = {2026},
  volume = {11},
  number = {32},
  pages = {47730--47738},
  doi = {10.1021/acsomega.6c02977}
}
Kostenlos starten →